Benjamin Looker Sells 11,824 Shares of Esperion Therapeutics (NASDAQ:ESPR) Stock

Esperion Therapeutics, Inc. (NASDAQ:ESPR) insider Benjamin Looker sold 11,824 shares of the firm’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $3.15, for a total value of $37,245.60. Following the sale, the insider directly owned 667,524 shares in the company, valued at $2,102,700.60. The trade was a 1.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Esperion Therapeutics Stock Performance

ESPR stock opened at $3.15 on Friday. Esperion Therapeutics, Inc. has a 1-year low of $0.95 and a 1-year high of $4.18. The firm has a market cap of $811.72 million, a PE ratio of -52.50 and a beta of 1.07. The business’s 50-day moving average price is $2.78 and its two-hundred day moving average price is $3.12.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Friday, May 8th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.08). The business had revenue of $80.10 million during the quarter, compared to the consensus estimate of $84.52 million. Esperion Therapeutics had a negative return on equity of 0.14% and a net margin of 0.12%.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Sivia Capital Partners LLC bought a new stake in Esperion Therapeutics in the 2nd quarter valued at approximately $25,000. R Squared Ltd acquired a new position in Esperion Therapeutics during the 3rd quarter worth approximately $33,000. Kestra Advisory Services LLC bought a new position in shares of Esperion Therapeutics during the 4th quarter worth approximately $35,000. KFG Wealth Management LLC bought a new position in shares of Esperion Therapeutics during the 4th quarter worth approximately $37,000. Finally, Cary Street Partners Financial LLC acquired a new stake in shares of Esperion Therapeutics in the fourth quarter valued at approximately $38,000. 47.39% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have commented on ESPR shares. Wall Street Zen upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, March 14th. Needham & Company LLC cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Citizens Jmp downgraded shares of Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Esperion Therapeutics in a report on Tuesday, April 21st. Finally, Piper Sandler cut shares of Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 1st. One research analyst has rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $5.54.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.